Cytori Therapeutics, Inc. Provides Business Update and Reports Second Quarter and First Half 2012 Results

SAN DIEGO, CA--(Marketwire - August 08, 2012) - During the second quarter and first half of 2012, Cytori Therapeutics (NASDAQ: CYTX) made key advancements in its cardiac cell therapy pipeline, achieved important commercial and regulatory milestones, carefully managed its financial resources and remained on plan to achieve $9 million in revenue for the year. The Company has achieved or made measurable progress in the following milestones, year-to-date:

Clinical Pipeline

• Received approval from the FDA to begin the U.S. ATHENA IDE trial for chronic myocardial ischemia in refractory heart failure patients. Patient screening is active and the first patient is expected to be treated shortly;
• Published positive six month outcomes from the APOLLO heart attack trial in the Journal of the American College of Cardiology;

Commercial Business

• Expanded Celution® CE Mark certification to include broader wound healing and ischemia related indications-for-use;
• Received regulatory approval for Celution® in Russia and Croatia and obtained multiple additional Puregraft® approvals worldwide;
• Applied for formal approval of the Celution® System for breast reconstruction from the Medical Technology Assessment Committee in the U.K;
• Published positive 12 month outcomes from the RESTORE 2 trial in the European Journal of Surgical Oncology;
• Advanced negotiations to expand our Celution® CE Mark into cardiovascular and ischemic indications;

Operations & Financial Performance

• Reduced net cash used in operating activities in the first half of 2012 compared to the first half of 2011, with related reductions in sales, general and administrative expenses;
• Received a U.S. composition patent for soft tissue defects and a U.S. device patent for accelerating the healing of wounds;
• Made tangible progress in several of our active partnership opportunities;

“Our cardiovascular disease pipeline progressed in the first half of 2012,” said Christopher J. Calhoun, chief executive officer for Cytori Therapeutics. “In the U.S., our refractory heart failure trial (ATHENA) is actively screening patients, our EU acute heart attack trial (ADVANCE) protocol has been revised and is back in front of key regulators, and progress has been made in leveraging our cardiovascular clinical data to expand our European market access. We are also broadening our global footprint of approvals and indications-for-use, which directly expands our access to new markets and presents commercial opportunities which can be addressed with existing resources. Lastly, we continued to improve operations by lowering our quarterly cash utilization rate, while maintaining our investment in clinical development and remaining on plan to achieve 2012 revenue guidance.”

Financial Results

Total revenues were $4.4 million and $5.9 million for the second quarter and first half of 2012, respectively, which includes $2.4 million in development revenue recognized in the second quarter of 2012. This compares to $2.4 million and $5.0 million for the same periods of 2011, respectively, which includes $1.2 million in development revenue recognized in the first quarter of 2011.

Product revenues were $1.9 million and $3.4 million for the second quarter and first half of 2012, compared with $2.4 million and $3.8 million for the same periods in 2011. Gross profit was $0.9 million and $1.5 million for the second quarter and first half of 2012, compared to $1.3 million and $1.8 million for the second quarter and first half of 2011, respectively. As previously reported, product sales will be weighted toward the second half of 2012, due in part to realizing the impact of new country approvals and expanded indications-for-use mentioned above.

Research and development expenses remained relatively stable at $3.2 million and $6.0 million for the second quarter and first half of 2012, compared to the same periods in 2011. In contrast, sales, general and administrative expenses were reduced to $6.4 million and $12.7 million in the second quarter and first half of 2012, a decrease of 19% and 13%, respectively, compared to the same periods in 2011. This improvement was achieved in part by targeted reductions in headcount and external consulting costs.

Net loss was $7.9 million, or ($0.13) per share, and $17.2 million, or ($0.30) per share, for the second quarter and first half of 2012, respectively. This compares to $5.1 million, or ($0.10) per share, and $17.2 million, or ($0.33) per share for the second quarter and first half of 2011, respectively. Net loss for the second quarter and first half of 2011 includes non-cash credit of $5.2 million and $2.1 million respectively related to the change in the fair value of warrant and option liabilities compared to non-cash expense of $0.7 million and $0.6 million for the same periods in 2012. At the end of the second quarter of 2012, Cytori had $25.8 million in cash and cash equivalents and $2.0 million in accounts receivable, net of reserves.

Management Conference Call Webcast and Shareholder Letter Information

Cytori will host a management conference call at 5:00 p.m. Eastern Time today to further discuss the company’s progress. The webcast will be available live and by replay two hours after the call and may be accessed under “Webcasts” in the Investor Relations section (http://ir.cytori.com) of Cytori’s website. If you are unable to access the webcast, you may dial in to the call at +1.866.791.6247, Passcode: 4549443. More details on our business are contained in the ‘August 2012 Shareholder Letter’ posted on the homepage of our Investor Relations website.

About Cytori

Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow, moderate the immune response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple “ischemic” conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori’s proprietary technologies and products, including the Celution® system product family. www.cytori.com

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position, such as the successful initiation of the ATHENA clinical trial of the Company’s Celution® system for chronic myocardial ischemia, our efforts to expand our CE Mark, achieve our revenue projection for 2012, and execute a commercialization partnership agreement. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks include clinical and regulatory uncertainties, such as those associated with the ATHENA clinical trial, including risks in the collection and results of clinical data, final clinical outcomes, dependence on third party performance, performance and acceptance of our products in the marketplace, and other risks and uncertainties described under “Risk Factors” in Cytori’s Securities and Exchange Commission Filings. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

 CYTORI THERAPEUTICS, INC. CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) ------------- ------------- As of As of June December 31, 30, 2012 2011 ------------- ------------- Assets Current assets: Cash and cash equivalents $ 25,771,000 $ 36,922,000 Accounts receivable, net of reserves of $220,000 and of $474,000 in 2012 and 2011, respectively 1,983,000 2,260,000 Inventories, net 3,108,000 3,318,000 Other current assets 1,115,000 837,000 ------------- ------------- Total current assets 31,977,000 43,337,000 Property and equipment, net 2,255,000 1,711,000 Restricted cash and cash equivalents 350,000 350,000 Investment in joint venture 164,000 250,000 Other assets 1,755,000 1,772,000 Intangibles, net 81,000 192,000 Goodwill 3,922,000 3,922,000 ------------- ------------- Total assets $ 40,504,000 $ 51,534,000 ============= ============= Liabilities and Stockholders’ Equity (Deficit) Current liabilities: Accounts payable and accrued expenses $ 5,066,000 $ 5,334,000 Current portion of long-term obligations 7,338,000 2,487,000 ------------- ------------- Total current liabilities 12,404,000 7,821,000 Deferred revenues, related party 1,107,000 3,520,000 Deferred revenues 5,296,000 5,244,000 Warrant liability 1,008,000 627,000 Option liability 2,100,000 1,910,000 Long-term deferred rent 600,000 504,000 Long-term obligations, net of discount, less current portion 17,441,000 21,962,000 ------------- ------------- Total liabilities 39,956,000 41,588,000 Commitments and contingencies Stockholders’ equity: Preferred stock, $0.001 par value; 5,000,000 shares authorized; -0- shares issued and outstanding in 2012 and 2011 -- -- Common stock, $0.001 par value; 95,000,000 shares authorized; 58,706,856 and 56,594,683 shares issued and outstanding in 2012 and 2011, respectively 59,000 57,000 Additional paid-in capital 260,146,000 252,338,000 Accumulated deficit (259,657,000) (242,449,000) ------------- ------------- Total stockholders’ equity 548,000 9,946,000 ------------- ------------- Total liabilities and stockholders’ equity $ 40,504,000 $ 51,534,000 ============= ============= CYTORI THERAPEUTICS, INC. CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) For the Three Months For the Six Months Ended June 30, Ended June 30, ------------------------ -------------------------- 2012 2011 2012 2011 ----------- ----------- ------------ ------------ Product revenues $ 1,947,000 $ 2,411,000 $ 3,427,000 $ 3,773,000 Cost of product revenues 1,032,000 1,109,000 1,885,000 1,950,000 ----------- ----------- ------------ ------------ Gross profit 915,000 1,302,000 1,542,000 1,823,000 ----------- ----------- ------------ ------------ Development revenues: Development, related party 2,413,000 -- 2,413,000 1,231,000 Research grant and other 16,000 11,000 19,000 15,000 ----------- ----------- ------------ ------------ 2,429,000 11,000 2,432,000 1,246,000 ----------- ----------- ------------ ------------ Operating expenses: Research and development 3,224,000 3,071,000 6,060,000 6,118,000 Sales and marketing 2,581,000 3,716,000 4,956,000 6,942,000 General and administrative 3,788,000 4,147,000 7,712,000 7,692,000 Change in fair value of warrant liability 251,000 (5,649,000) 381,000 (2,178,000) Change in fair value of option liability 460,000 400,000 190,000 110,000 ----------- ----------- ------------ ------------ Total operating expenses 10,304,000 5,685,000 19,299,000 18,684,000 ----------- ----------- ------------ ------------ Operating loss (6,960,000) (4,372,000) (15,325,000) (15,615,000) ----------- ----------- ------------ ------------ Other income (expense): Interest income 1,000 1,000 2,000 4,000 Interest expense (860,000) (696,000) (1,726,000) (1,434,000) Other income (expense), net (27,000) (15,000) (73,000) (62,000) Equity loss from investment in joint venture (37,000) (56,000) (86,000) (102,000) ----------- ----------- ------------ ------------ Total other income (expense) (923,000) (766,000) (1,883,000) (1,594,000) ----------- ----------- ------------ ------------ Net loss $(7,883,000) $(5,138,000) $(17,208,000) $(17,209,000) ----------- ----------- ------------ ------------ Basic and diluted net loss per common share $ (0.13) $ (0.10) $ (0.30) $ (0.33) =========== =========== ============ ============ Basic and diluted weighted average common shares 58,676,092 52,411,642 58,080,541 52,204,348 =========== =========== ============ ============ CYTORI THERAPEUTICS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) For the Six Months Ended June 30, ---------------------------- 2012 2011 ------------- ------------- Cash flows from operating activities: Net loss $ (17,208,000) $ (17,209,000) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 453,000 400,000 Amortization of deferred financing costs and debt discount 470,000 471,000 Provision for doubtful accounts 19,000 235,000 Change in fair value of warrants 381,000 (2,178,000) Change in fair value of option liabilities 190,000 110,000 Share-based compensation expense 1,977,000 1,721,000 Equity loss from investment in joint venture 86,000 102,000 Increases (decreases) in cash caused by changes in operating assets and liabilities: Accounts receivable 258,000 (623,000) Inventories 210,000 (513,000) Other current assets (278,000) (15,000) Other assets 17,000 (905,000) Accounts payable and accrued expenses (268,000) 92,000 Deferred revenues, related party (2,413,000) (1,231,000) Deferred revenues 52,000 35,000 Long-term deferred rent 96,000 (24,000) ------------- ------------- Net cash used in operating activities (15,958,000) (19,532,000) ------------- ------------- Cash flows from investing activities: Purchases of property and equipment (886,000) (433,000) ------------- ------------- Net cash used in investing activities (886,000) (433,000) ------------- ------------- Cash flows from financing activities: Principal payments on long-term obligations (140,000) (2,230,000) Proceeds from exercise of employee stock options 951,000 2,756,000 Proceeds from sale of common stock 4,946,000 -- Costs from sale of common stock (64,000) -- ------------- ------------- Net cash provided by financing activities 5,693,000 526,000 ------------- ------------- Net decrease in cash and cash equivalents (11,151,000) (19,439,000) Cash and cash equivalents at beginning of period 36,922,000 52,668,000 ------------- ------------- Cash and cash equivalents at end of period $ 25,771,000 $ 33,229,000 ============= =============